BM-1244 (APG-1252-M1) is a potent Bcl-xL/Bcl-2 inhibitor (antagonist) with Ki of 134 and 450 nM for Bcl-xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with EC50 of 5 nM.

Physicochemical Properties

Molecular Formula	C54H59CLF4N6O8S4
Molecular Weight	1159.79
Exact Mass	1158.29
CAS #	1619923-32-8
Related CAS #	Pelcitoclax;1619923-36-2
PubChem CID	90279478
Appearance	White to off-white solid powder
LogP	8.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	18
Rotatable Bond Count	19
Heavy Atom Count	77
Complexity	2240
Defined Atom Stereocenter Count	1
SMILES	C1C(C2C(=C(N(C=2C2C=CC(Cl)=CC=2)C(C)C)C)S(C)(=O)=O)=CC(=CC=1F)N1CCN(C2=CC=C(C=C2)NS(=O)(=O)C2=CC(=C(C=C2)N[C@@H](CSC2C=CC=CC=2)CCN2CCC(C(O)=O)CC2)S(C(F)(F)F)(=O)=O)CC1
InChi Key	OGHPBBHWAPIYHS-VZUYHUTRSA-N
InChi Code	InChI=1S/C54H59ClF4N6O8S4/c1-35(2)65-36(3)52(75(4,68)69)50(51(65)37-10-12-40(55)13-11-37)39-30-41(56)32-45(31-39)64-28-26-63(27-29-64)44-16-14-42(15-17-44)61-77(72,73)47-18-19-48(49(33-47)76(70,71)54(57,58)59)60-43(34-74-46-8-6-5-7-9-46)22-25-62-23-20-38(21-24-62)53(66)67/h5-19,30-33,35,38,43,60-61H,20-29,34H2,1-4H3,(H,66,67)/t43-/m1/s1
Chemical Name	1-[(3R)-3-[4-[[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-4-methylsulfonyl-1-propan-2-ylpyrrol-3-yl]-5-fluorophenyl]piperazin-1-yl]phenyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperidine-4-carboxylic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1. [2]. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343.

Solubility Data

Solubility (In Vitro)

DMSO : 200 mg/mL (172.45 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 5 mg/mL (4.31 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	0.8622 mL	4.3111 mL	8.6223 mL
	5 mM	0.1724 mL	0.8622 mL	1.7245 mL
	10 mM	0.0862 mL	0.4311 mL	0.8622 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.